SiVEC Biotechnologies
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
SiVEC Biotech is developing first-in-class therapies, with a focus on oncology and gene-editing, using its proprietary BactPac™ delivery platform. Named Top Emerging Company at BIO 2022, BactPac uses engineered bacteria to deliver biologics, including mRNA, siRNA, proteins, and gene editors, with precision and safety that outperforms traditional delivery methods. SiVEC’s lead asset, SVC-KRAb™, is a pan-RAS biologic targeting a broad range of RAS mutations common in pancreatic, lung, and colorectal cancers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}